الملخص
Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgically failed case of OSSN instead of IFNα-2b. In this case report, we have shared our initial experience with the novel use of peg-IFNα-2a to treat OSSN. According to our brief clinical experience, peg-IFNα-2a is nontoxic to ocular surface and has a promising role to treat OSSN.
الكلمات المفتاحية
بيانات النشر
- المعرّف الرقمي
- 10.4103/ojo.ojo_146_21
- المجلة
- المجلة العُمانية لطب العيون, 15(1), 81-84
- الناشر
- منشورات ميدنو
- وصول مفتوح
- وصول مفتوح ذهبي
اقتبس هذه المقالة
APA 7
Nuruddin, M., Roy, S. R., & Hoque, F. (2022). Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia. Oman Journal of Ophthalmology, 15(1), 81-84. https://doi.org/10.4103/ojo.ojo_146_21
MLA 9
Nuruddin, Murtuza, et al. "Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia." Oman Journal of Ophthalmology, vol. 15, no. 1, 2022, pp. 81-84. https://doi.org/10.4103/ojo.ojo_146_21.
شيكاغو (المؤلف–التاريخ)
Nuruddin, Murtuza, Soma Rani Roy, and Fahmida Hoque. 2022. "Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia." Oman Journal of Ophthalmology 15 (1): 81-84. https://doi.org/10.4103/ojo.ojo_146_21.
هارفارد
Nuruddin, M., Roy, S. R. and Hoque, F. (2022) 'Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia', Oman Journal of Ophthalmology, 15(1), pp. 81-84. doi:10.4103/ojo.ojo_146_21.
فانكوفر
Nuruddin M, Roy SR, Hoque F. Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia. Oman Journal of Ophthalmology. 2022;15(1):81-84. doi:10.4103/ojo.ojo_146_21
IEEE
M. Nuruddin, S. R. Roy, and F. Hoque, "Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia," Oman Journal of Ophthalmology, vol. 15, no. 1, pp. 81-84, 2022, doi: 10.4103/ojo.ojo_146_21.